Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease.
Moris SanginetoFelix GrabherrTimon Erik AdolphChristoph GranderSimon ReiderNikolai JaschkeLisa MayrJulian SchwärzlerMarcello DallioAlexander R MoschenAntonio MoschettaCarlo SabbàHerbert TilgPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
Dimethyl-fumarate counteracts ethanol-induced barrier dysfunction, suppresses inflammatory responses of KCs and ameliorates hepatic inflammation and steatosis, hallmarks of experimental ALD. Our data indicates that DMF treatment might be beneficial in human ALD and respective clinical trials are eagerly awaited.
Keyphrases
- oxidative stress
- clinical trial
- diabetic rats
- endothelial cells
- high glucose
- mouse model
- electronic health record
- insulin resistance
- high fat diet
- drug induced
- pluripotent stem cells
- randomized controlled trial
- big data
- metabolic syndrome
- alcohol consumption
- high fat diet induced
- open label
- replacement therapy
- deep learning